首页> 外文期刊>Biopharmaceutics and Drug Disposition >Characterisation of the human liver in vitro metabolic pattern of artemisinin and auto-induction in the rat by use of nonlinear mixed effects modelling.
【24h】

Characterisation of the human liver in vitro metabolic pattern of artemisinin and auto-induction in the rat by use of nonlinear mixed effects modelling.

机译:使用非线性混合效应模型表征人肝中青蒿素的体外代谢模式并在大鼠中自动诱导。

获取原文
获取原文并翻译 | 示例
           

摘要

Aims: The aims of the study were to characterise the metabolic pattern of artemisinin in human and rat liver microsomes and to assess the magnitude of auto-induction in the rat.Methods: (14)C-artemisinin was incubated with human liver microsomes and with liver microsomes from rats pretreated with oral artemisinin or placebo. The metabolic fate of (14)C-artemisinin in microsomes from human B-lymphoblastoid cell lines transformed with CYP2A6, CYP2B6 and CYP3A4 was also investigated. The human liver microsome data and the rat liver microsomes data were analysed by nonlinear mixed effects modelling and naive pooling using NONMEM, respectively.Results: Four metabolites were radiometrically detected in experiments with rat liver microsomes. The model that best described the data involved three primary metabolites of which one metabolite was further metabolised to a secondary metabolite. The formation of the four metabolites was induced 2.8, 7.2, 4.8 and 2.5-fold, respectively, in liver microsomes from rats pre-treated with artemisinin. Three metabolites were formed in human liver microsomes; having the same retention times as three of the metabolites formed in the rat. The final model consisted of two primary metabolites and a secondary metabolite with CYP2B6 and CYP2A6 influencing the formation rates of the major and minor primary metabolites, respectively.Conclusions: CYP2B6 and CYP2A6 activities described variability in the formation of the major and minor primary metabolites, respectively, in human liver microsomes. All artemisinin metabolic pathways in rat liver microsomes were induced in artemisinin pretreated animals. We suggest modelling as a method for the discrimination and detection of more complex metabolic patterns from in vitro metabolism rate data. Copyright 2002 John Wiley & Sons, Ltd.
机译:目的:本研究的目的是表征青蒿素在人和大鼠肝微粒体中的代谢模式,并评估大鼠自体诱导的程度。方法:(14)C-青蒿素与人肝微粒体和肝素一起孵育口服青蒿素或安慰剂预处理的大鼠肝脏微粒体。还研究了(14)C-青蒿素在由CYP2A6,CYP2B6和CYP3A4转化的人B淋巴母细胞系中的微粒体中的代谢命运。通过非线性混合效应模型和使用NONMEM的幼稚池分析了人肝微粒体数据和大鼠肝微粒体数据。结果:在大鼠肝微粒体的实验中,辐射测定了四种代谢物。最能描述数据的模型涉及三种主要代谢物,其中一种代谢物被进一步代谢为次要代谢物。在用青蒿素预处理的大鼠的肝微粒体中,四种代谢物的形成分别被诱导了2.8倍,7.2倍,4.8倍和2.5倍。人肝微粒体中形成了三种代谢物。具有与大鼠中形成的三种代谢物相同的保留时间。最终模型由两种主要代谢物和一种次要代谢物组成,其中CYP2B6和CYP2A6分别影响主要和次要主要代谢物的形成速率。 ,在人肝微粒体中。在大鼠青蒿素预处理的动物中诱导了大鼠肝微粒体中的所有青蒿素代谢途径。我们建议建模作为一种方法,用于从体外代谢率数据中识别和检测更复杂的代谢模式。版权所有2002 John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号